Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations

Respiratory Research

Table 3 Reduced STATCOPE development cohort model. Time-dependent multivariable Cox proportional hazards analyses for risk of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bilirubin prior to first AECOPD

Parameter	aHR	95% CI	p-value
STATCOPE Reduced Development Cohort Model
Treatment assignment	0.92	0.77–1.11	0.38
Male sex	0.86	0.72–1.04	0.12
Black race	0.66	0.51–0.84	<0.001
BMI (kg/m²)	0.98	0.97–1.00	0.02
Chronic bronchitis	1.17	0.97–1.42	0.11
Supplemental oxygen use	1.37	1.12–1.67	0.002
SGRQ score	1.02	1.01–1.02	<0.001
Inhaler use^a - none (0 of 3 classes: LABA, LAMA, ICS)	0.52	0.36–0.76	0.007
Inhaler use^a - 1 of 3 classes	0.91	0.68–1.22	0.12
Inhaler use^a - 2 of 3 classes	0.72	0.58–0.90	0.51
Steroid or antibiotic use in year prior to enrollment	1.62	1.22–2.16	0.001
BILIRUBIN (per log ₁₀ increase)	0.89	0.74–1.09	0.26

Abbreviations: BMI body mass index, ICS inhaled corticosteroid, LABA long-acting beta agonist, LAMA long-acting antimuscarinic, SGRQ St. George’s Respiratory Questionnaire
^aReferent group is 3-class inhaler therapy (long-acting beta agonist, long-acting antimuscarinic, and inhaled corticosteroid)
Bilirubin is presented in bold, as this was the primary predictor variable

ISSN: 1465-993X